This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gallo, J. M. Articles by O'Dwyer, P. J. Search for Related Content PubMed PubMed Citation Articles by Gallo, J. M. Articles by O'Dwyer, P. J.

Time-dependent Pharmacodynamic Models in Cancer Chemotherapy: Population Pharmacodynamic Model for Glutathione Depletion following Modulation by Buthionine Sulfoximine (BSO) in a Phase I Trial of Melphalan and BSO

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111

The development of time-dependent pharmacodynamic models in cancer chemotherapy has been extremely limited. A population approach was used to develop such a model to describe the effect of buthionine sulfoximine (BSO), via its active S-isomer (S-BSO), on glutathione (GSH) depletion in peripheral mononuclear cells. The Phase I trial utilized escalating doses of BSO, from 5 to 17 gm/m², as a multiple infusion regimen. The population model consisted of a linear 2-compartment pharmacokinetic model coupled to an indirect response model. The indirect response model consisted of a GSH compartment with input and output rate processes that are modulated as a function of S-BSO and GSH concentrations. The model predicted the observed gradual depletion of GSH, a nadir at approximately 30 h after the last dose of BSO, and a return to baseline GSH levels. On the basis of an IC₅₀ estimate of about 1.6 µM for inhibition of -glutamylcysteine synthetase, the target enzyme of BSO, the population model predicted near identical GSH concentration time profiles over the dose range studied. Time-dependent pharmacodynamic models are seen as a powerful means to design dosing regimens and to provide a mathematical platform for mechanistic based models.

¹ To whom requests for reprints should be addressed, at Fox Chase Cancer Center, Department of Medical Oncology, 7701 Burholme Avenue, Philadelphia, PA 19111.

Received 7/11/95. Accepted 8/29/95.

This article has been cited by other articles:

				P. Kuppusamy, H. Li, G. Ilangovan, A. J. Cardounel, J. L. Zweier, K. Yamada, M. C. Krishna, and J. B. Mitchell Noninvasive Imaging of Tumor Redox Status and Its Modification by Tissue Glutathione Levels Cancer Res., January 1, 2002; 62(1): 307 - 312. [Abstract] [Full Text] [PDF]

				J. M. Gallo, P. B. Laub, E. K. Rowinsky, L. B. Grochow, and S. D. Baker Population Pharmacokinetic Model for Topotecan Derived From Phase I Clinical Trials J. Clin. Oncol., June 12, 2000; 18(12): 2459 - 2467. [Abstract] [Full Text] [PDF]

				A. Margalit, S. D. Hauser, B. S. Zweifel, M. A. Anderson, and P. C. Isakson Regulation of prostaglandin biosynthesis in vivo by glutathione Am J Physiol Regulatory Integrative Comp Physiol, February 1, 1998; 274(2): R294 - R302. [Abstract] [Full Text] [PDF]